triple agonist glp-1 LY3437943, a novel glucagon, GIP, and receptor for glycemic control and weight loss: From discovery to clinical proof of concept: Cell Metabolism Dual and Triple Gut Peptide

Efficacy and safety of once-weekly semaglutide 2.4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial

Youll learn what tests you need, when to get them, and why theyre important

doi: 10.1152/physrev.00034.2006 [DOI] [PubMed] [Google Scholar] 36

Retatrutide represents a next generation approach for patients who want more comprehensive metabolic support

In addition, an inverse correlation between circulating free fatty acids and GLP-1 concentrations have been found in vivo and in vitro experiments, and systemic GLP-1 levels can be increased in obese patients after treatment with acipimox [94]

Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, et al